I am working on designing a covalent inhibitor for a kinase. We are using the ADPGlo kinase assay kit from Promega to assess the potency. Both assay and storage buffers have 0.25 mM DTT in them. Also, the receptor storage buffer has 10 mM glutathione.
So, I am not sure, if the Cys is already in the reduced form, would a covalent inhibitor competes with DTT to form a covalent bond with the target Cys? Or should we consider reducing the DTT concentration?